Introduction: High-fat diet (HFD) leads to obesity which causes low grade inflammation and changes in adipokines and hepatokines. Metabolic surgery, like ileal transposition (IT) leads to beneficial metabolic effect and lowers inflammatory state. However these positive effects diminish with time and data related to dietary factors modifying these effects are scare.
Aim: To assess influence of HFD on plasma adiponectin, leptin, betatrophin and pentraxin 3 (PTX3) in obese rats undergoing metabolic surgery.
Methods: There were 24 rats fed for 8 weeks with HFD to induce obesity. After 8 weeks half of them underwent IT and half of them SHAM surgery. For 8 weeks after surgery half of the rats in the IT and in the SHAM group were fed with HFD and half of them with control diet (CD). After 8 weeks following surgery adipokines namely adiponectin and leptin as well as hepatokine namely betatrophin and inflammatory protein PTX3 were assessed.
Outcomes: When comparing HFD to CD groups following two surgery procedures rats who underwent IT comparing to SHAM surgery had significantly higher concentration of betatrophin (1751.2 vs 594.5 pg/ml; P=0.0041) when continued to be fed with HFD as well as when the diet was changed to CD (2391.2 vs 922.9 pg/ml; P=0.0047) and significantly higher concentration of adiponectin (72.6 vs 28.7 ng/ml; P=0.007) only among those rats who continued to be fad with HFD. There was higher concentration of betatrophin observed among rats who were postoperatively fed with HFD comparing to rats who were fed with CD in the IT surgery group but the difference was not significant (2301.2 vs 1751.2 pg/ml; P= 0.0552). There was no difference in PTX3 and leptin observed among IT compared to SHAM operated animals in relation to diet.
Conclusion: The study indicates that diet may modify the effects of metabolic surgery on adiponectin and betatrophin which are hormones influencing metabolic state and this may serve as a motivation to investigate this phenomenon in humans.
K. Nabrdalik: None. T. Sawczyn: None. D.M. Stygar: None. J. Gumprecht: Consultant; Self; Astra, Bioton, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck & Co., Inc., Merck Sharp & Dohme Corp., Mundipharma International, Novo Nordisk A/S, Polfa Tarchomin S.A., Sanofi, Servier. Speaker’s Bureau; Self; Astra, Bioton, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck & Co., Inc., Merck Sharp & Dohme Corp., Mundipharma International, Novo Nordisk A/S, Polfa Tarchomin S.A., Sanofi, Servier.
